Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model

Laboratory Investigation

Volumn 92, Issue 8, 2012, Pages 1115-1128

  Xin, Xiping ^a   Majumder, Mousumi ^a   Girish, Gannareddy V ^a   Mohindra, Vik ^a   Maruyama, Takayuki ^b   Lala, Peeyush K ^a  

^a WESTERN UNIVERSITY   (Canada)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

breast cancer therapy; COX 2; EP4 antagonist; lung metastasis; lymphangiogenesis; lymphatic metastasis; VEGF C and D

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MATRIGEL; ONO 8713; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CANCER MODEL; CELL MIGRATION; CONTROLLED STUDY; FEMALE; INGUINAL REGION; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; LUNG NEOPLASMS; LYMPHANGIOGENESIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84864458283     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.90     Document Type: Article

References (54)

1. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-7916.
2. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007;26:525-534.
3. Harris RE. Humana Press: Totowa, NJ, 2003.
4. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
5. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-54057.
6. Howe LR, Chang SH, Tolle KC, et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005;65:10113-10119.
7. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62:632-635.
8. Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-434.
9. Zhang XH, Huang DP, Guo GL, et al. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 2008;8:4.
10. Ranger GS, Thomas V, Jewell A, et al. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 2004;24:2349-2351.
11. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006;6:27.
12. Lala PK, Parhar RS, Singh P. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumorbearing mice and prevents tumor metastasis. Cell Immunol 1986;99:108-118.
13. Lala PK, Al-Mutter N, Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 1997;73:371-380.
14. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001;93: 497-506.
15. Timoshenko AV, Xu G, Chakrabarti S, et al. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003;289:265-274.
16. Timoshenko AV, Lala PK, Chakraborty C. PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. Int J Cancer 2004;108:384-389.
17. Timoshenko AV, Chakraborty C, Wagner GF, et al. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006;94:1154-1163.
18. Pepper MS, Tille JC, Nisato R, et al. Lymphangiogenesis and tumor metastasis. Cell Tissue Res 2003;314:167-177.
19. Vleugel MM, Bos R, van der GP, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 2004;57:746-751.
20. Van dA I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 2005;11:7637-7642.
21. Bhattacharjee RN, Timoshenko AV, Cai J, et al. Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Sci 2010;101:2026-2032.
22. van IV, Leidenius M, von SK, et al. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am J Clin Pathol 2007;128:759-766.
23. Timoshenko AV, Rastogi S, Lala PK. Migration-promoting role of VEGFC and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 2007;97:1090-1098.
24. Perrone G, Santini D, Vincenzi B, et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 2005;46:561-568.
25. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;35:1709-1711.
26. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006;296:1653-1656.
27. Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-690.
28. Fujino H, Xu W, Regan JW. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003;278:12151-12156.
29. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-11617.
30. Kundu N, Ma X, Holt D, et al. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 2009;117:235-242.
31. Parhar RS, Lala PK. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J Leukoc Biol 1988;44:474-484.
32. Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007;67:4507-4513.
33. Lala PK, Parhar RS. Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy. Int J Cancer 1993;54:677-684.
34. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002;109:883-893.
35. Kabashima K, Sakata D, Nagamachi M, et al. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003;9:744-749.
36. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-Larginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999;155:1381-1390.
37. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002;62:5778-5784.
38. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-9672.
39. Belien JA, Somi S, de Jong JS, et al. Fully automated microvessel counting and hot spot selection by image processing of whole tumor sections in invasive breast cancer. J Clin Pathol 1999;52:184-192.
40. George RJ, Sturmoski MA, Anant S, et al. EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 2007;83:112-120.
41. Barnes NL, Warnberg F, Farnie G, et al. Cyclooxygenase-2 inhibition: effects on tumor growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 2007;96:575-582.
42. Iwata C, Kano MR, Komuro A, et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 2007;67:10181-10189.
43. Kawamori T, Uchiya N, Nakatsugi S, et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 2001;22:2001-2004.
44. Chang SH, Ai Y, Breyer RM, et al. The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res 2005;65:4496-4499.
45. Robertson FM, Simeone AM, Lucci A, et al. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer 2010;116:2806-2814.
46. Hosono K, Suzuki T, Tamaki H, et al. Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation. Arterioscler Thromb Vasc Biol 2011;31:1049-1058.
47. Ma X, Kundu N, Rifat S, et al. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006;66:2923-2927.
48. Ma X, Kundu N, Ioffe OB, et al. Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res 2010;8:1310-1318.
49. Terada N, Shimizu Y, Kamba T, et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 2010;70:1606-1615.
50. Girish G, Radan L, Tutunea-Fatan E, et al. Role of prostaglandin E2 in breast cancer-associated lymphangiogenesis in an in vitro system. Proc Amer Assoc Cancer Res 2010;51:151-152.
51. Bhattacharjee RN, Lala PK. Role of toll-like receptors in COX-2 mediated VEGF-C upregulation in breast cancer. Proc Amer Assoc Cancer Res 2009;50:371.
52. Worden B, Yang XP, Lee TL, et al. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 2005;65:7071-7080.
53. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009;17:55-67.
54. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-1308.